Dyskinesia - Pipeline Review, H2 2018

Dyskinesia - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2018, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 16, 4, 17, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Dyskinesia - Overview 6
Dyskinesia - Therapeutics Development 7
Dyskinesia - Therapeutics Assessment 16
Dyskinesia - Companies Involved in Therapeutics Development 24
Dyskinesia - Drug Profiles 36
Dyskinesia - Dormant Projects 159
Dyskinesia - Discontinued Products 162
Dyskinesia - Product Development Milestones 163
Appendix 175

List Of Tables


Number of Products under Development for Dyskinesia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2018
Dyskinesia - Pipeline by Advicenne SA, H2 2018
Dyskinesia - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
Dyskinesia - Pipeline by Avanir Pharmaceuticals Inc, H2 2018
Dyskinesia - Pipeline by Cadent Therapeutics, H2 2018
Dyskinesia - Pipeline by Cavion LLC, H2 2018
Dyskinesia - Pipeline by Cerevance Inc, H2 2018
Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2018
Dyskinesia - Pipeline by DanPET AB, H2 2018
Dyskinesia - Pipeline by EpiVax Inc, H2 2018
Dyskinesia - Pipeline by H. Lundbeck AS, H2 2018
Dyskinesia - Pipeline by Heptares Therapeutics Ltd, H2 2018
Dyskinesia - Pipeline by India Globalization Capital Inc, H2 2018
Dyskinesia - Pipeline by Ipsen SA, H2 2018
Dyskinesia - Pipeline by IRLAB Therapeutics AB, H2 2018
Dyskinesia - Pipeline by Medy-Tox Inc, H2 2018
Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2018
Dyskinesia - Pipeline by Mylan NV, H2 2018
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2018
Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H2 2018
Dyskinesia - Pipeline by Neurolixis Inc, H2 2018
Dyskinesia - Pipeline by Newron Pharmaceuticals SpA, H2 2018
Dyskinesia - Pipeline by Phenomenome Discoveries Inc, H2 2018
Dyskinesia - Pipeline by Revance Therapeutics Inc, H2 2018
Dyskinesia - Pipeline by Sage Therapeutics Inc, H2 2018
Dyskinesia - Pipeline by SOM Biotech SL, H2 2018
Dyskinesia - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2018
Dyskinesia - Dormant Projects, H2 2018
Dyskinesia - Dormant Projects, H2 2018 (Contd..1), H2 2018
Dyskinesia - Dormant Projects, H2 2018 (Contd..2), H2 2018
Dyskinesia - Discontinued Products, H2 2018

List Of Figures


Number of Products under Development for Dyskinesia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Tardive Dyskinesia Global Clinical Trials Review, H2, 2018

Tardive Dyskinesia Clinical Trials Review, H2, 2018 Clinical trial report, “Tardive Dyskinesia  Clinical Trials Review, H2, 2018 provides an overview of Tardive Dyskinesia clinical trials scenario. This

USD 2500 View Report

Dyskinesia - Pipeline Review, H2 2018

Dyskinesia - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2018, provides an overview of the Dyskinesia (Central Nervous System)

USD 2000 View Report

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T

USD 3500 View Report

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available